Kuramoto T, Hirano R, Kuwamura M et al. (2010) Identification of the rat Rex mutation as a 7-bp deletion at splicing acceptor site of the Krt71 gene. It has been shown that a side population (SP), which is characterized by high chemical efflux capacity, is present in human melanoma cell lines. However, it was not clear whether patients' samples contain the same subpopulation. In this issue, Luo et al. (2012) report that they have isolated SP cells directly from patients' melanomas. SP cells are resistant to paclitaxel because of the upregulation of ABCB1 and ABCB5. Notably, these cells are also resistant to temozolomide, which is not a substrate for ATP-Binding Cassette (ABC) transporters, in an interleukin (IL)-8-dependent manner. This study provides novel clues for understanding how a small, but critical, subpopulation within melanomas is resistant to therapies. A gradient of fluorescence of the dye monitored by flow cytometry at both wavelengths is usually seen as a commalike region on an x-y plot. The tip of the comma-like region forms a tail, which displays low blue and red fluorescence. This subpopulation, termed 'side population', has high efflux capacity and has been identified in several tissues of mammalian species (Goodell et al., 1996) . Likely, the increased efflux capacity of the SP is promoted through ABC transporters. Most commonly, ABCB1 and ABCG2 are highly expressed in SPs of many tissue types and are responsible for transporting Hoechst 33342, as well as chemotherapeutic drugs; vinblastin and paclitaxel are expelled by ABCB1, whereas topotecan and methotrexate are the substrates of ABCG2 (Hadnagy et al., 2006) .
The SP assay initially attracted attention among stem cell researchers as a strategy to isolate potential stem/progenitor cells from various tissues, because cell surface markers for stem cells are still not defined in many organ systems. More recently, the assay has been used with cell lines and patient-derived tumor material from various types of cancer to identify cells that exhibit stem cell-like properties. Several groups have characterized SP cells in melanoma (Grichnik et al., 2006 (Grichnik et al., 2006) , slow growing (Grichnik et al., 2006; Roesch et al., 2010) , and, most importantly, resistant to chemotherapy (FukunagaKalabis et al., 2010; Wouters et al., 2012) . Although these studies with cell lines suggest that melanomas contain a subpopulation intrinsically resistant to chemotherapeutic drugs, it remains unclear whether the SP phenotype is clinically relevant or more of a culture artifact.
In this issue, Luo et al. (2012) report that patients' melanomas indeed do contain an SP. They performed the Hoechst assay on suspensions of melanoma cells, which were directly isolated from tumor tissues and patient-derived tumor xenografts (PDX model). Original tumors showed the presence of SP cells ranging from 0.1 to 0.7%, regardless of whether the lesions were primary or metastatic. Melanoma cell lines from previous and the current studies showed a heightened fraction of SP cells, close to 10% of the total population. It is likely that in vitro culture systems provide a selective pressure for the expansion of specific tumor subpopulations. PDX tumors showed a similar percentage of SP cells compared with their original tumor, indicating that this in vivo model has the significant advantage of maintaining the heterogeneity of the tumors of origin. Both paclitaxel and temozolomide treatment, the former is the substrate of ABCB1 and the latter is not, increased the ratio of SP cells in the remaining tumors of PDX mice, suggesting that SP cells in melanoma are resistant to chemotherapy in vivo. Melanoma SP cells showed higher expression of multiple ABC transporters, including ABCB1 and ABCB5, compared with the non-SP fraction. When these two ABC members were knocked down in a melanoma cell line, the percentage of the SP was significantly decreased, and the cells regained sensitivity to paclitaxel. Knocking down neither ABCB1 nor ABCB5 affected the response to temozolomide in melanoma. The authors further explored the mechanism responsible for temozolomide resistance of SP cells. The patientderived SP cells highly expressed IL-8, which has been suggested to be associated with chemoresistance in melanoma cells. Blocking IL-8 signaling with neutralizing antibodies or small interfering RNA significantly increased sensitivity to temozolomide in vitro (the former specifically decreased the resistance in a SP). Moreover, microarray data revealed that SP cells are enriched with components of the inflammatory response, especially in the NF-kB signaling pathway, which may contribute to chemoresistance in an ABC transporter-independent manner. These findings suggest that not only efflux capacity, but also other intrinsic mechanisms confer the resistance of melanoma SP cells against multiple drugs, which are not substrates for ABC transporters. Further studies are warranted to determine whether the inhibition of IL-8 or NF-kB signaling can reverse drug resistance of melanoma cells in vivo. Such studies will contribute to progress in the therapy of this tumor, which remains challenging to treat.
